Trial Profile

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pabinafusp alfa (Primary)
Indications Mucopolysaccharidosis II
Focus Adverse reactions
Sponsors JCR Pharmaceuticals

Most Recent Events

14 Feb 2024 Results published in a JCR Pharmaceuticals Media Release.
14 Feb 2024 According to JCR Pharmaceuticals, long-term efficacy and safety data from Japanese and Brazilian study were presented at the 20th Annual WORLDSymposium, 2024.
27 Feb 2023 According to a JCR Pharmaceuticals media release, data from this study were presented at the 19th Annual WORLDSymposium™ 2023 in Orland, FL, USA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com